1-Propyl-5-MeO-AMT, also known as 1-propyl-5-methoxy-α-methyltryptamine, is a serotonin receptor modulator of the tryptamine, α-alkyltryptamine, and 5-methoxytryptamine families.[1][2][3] It is the 1-propyl derivative of 5-methoxy-α-methyltryptamine (5-MeO-AMT).[3]

Whereas most tryptamines are highly non-selective in terms of binding to serotonin receptors, 1-propyl-5-MeO-AMT shows selectivity for the serotonin 5-HT2A receptor.[1][2][3] Its affinities (Ki) for serotonin receptors were 12 nM for the serotonin 5-HT2A receptor, 120 nM for the serotonin 5-HT2C receptor, 5,000 nM for the serotonin 5-HT1B receptor, 7,100 nM for the serotonin 5-HT1A receptor, and >10,000 nM for the serotonin 5-HT1D receptor, whereas other serotonin receptors were not reported.[3] Its capacity and potency in activating the serotonin receptors was also not reported.[3]

The drug was developed by Richard Glennon and colleagues and was first described in 1990.[3] At the time, it was described as the most 5-HT2A receptor-selective tryptamine known to date.[3]

See also

References

  1. ^ a b Araújo AM, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M (August 2015). "The hallucinogenic world of tryptamines: an updated review". Archives of Toxicology. 89 (8): 1151–1173. Bibcode:2015ArTox..89.1151A. doi:10.1007/s00204-015-1513-x. PMID 25877327. Like phenylalkylamines, the tryptamine hallucinogens such as LSD, psilocin, DMT or 5-MeO-DMT act as 5-HT2 receptor agonists, but they are much less selective, binding to a variety of 5-HT1 and 5-HT2 receptor subtypes (including 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2A and 5-HT2C receptors) with different affinities (Blair et al. 2000; Fantegrossi et al. 2006, 2008a; McKenna et al. 1990; Peden et al. 1981; Strassman et al. 1996; Winter et al. 2000). For example, N1-n-propyl-5-methoxyα-methyltryptamine binds preferentially at 5-HT2 receptors (Glennon et al. 1990), while 5-MeO-DIPT has a considerably increased affinity for 5-HT1A receptors, although it also has affinity for 5-HT2A and 5-HT2C receptors (Fantegrossi et al. 2006).
  2. ^ a b Vangveravong S (1994). "Synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues". ProQuest. ProQuest 304131663. Retrieved 22 March 2025. For example, 1-n-propyl-5-methoxy-α-methyltryptamine binds with significant affinity and selectivity at the 5-HT2 receptor relative to other 5-HT receptors.76 [...] 76. Glennon. R. A.; Chaurasia, Titeler, M. Binding of Indolylalkylamines at 5-HT Serotonin Receptors: Examination of a Hydrophobic Binding Region. J. Med. Chen 1990, 33, 2777-2784.
  3. ^ a b c d e f g Glennon RA, Chaurasia C, Titeler M (October 1990). "Binding of indolylalkylamines at 5-HT2 serotonin receptors: examination of a hydrophobic binding region". Journal of Medicinal Chemistry. 33 (10): 2777–2784. doi:10.1021/jm00172a016. PMID 2213830. Whereas tryptamine derivatives generally display little selectivity for the various populations of 5-HT receptors, N1-n-propyl-5-methoxy-α-methyltryptamine (3h) binds with significant affinity (Ki = 12 nM) and selectivity at 5-HT2 receptors relative to 5-HT1A (Ki = 7100 nM), 5-HT1B (Ki = 5000 nM), 5-HT1C (Ki = 120 nM), and 5-HT1D (Ki > 10000 nM) receptors. As a consequence, this is the most 5-HT2-selective indolylalkylamine derivative reported to date.
Allikas: https://en.wikipedia.org/wiki/1-Pr-5-MeO-AMT
No tags for this post.